Cubist Seeks to Expand Entereg's Indication

Cubist Pharmaceuticals announced that it has submitted a supplemental new drug application (sNDA) to the FDA requesting approval for the use of Entereg (alvimopan) to accelerate GI recovery following any surgery that includes a bowel resection with primary anastomosis; expanded from the current indication in patients requiring surgery for colorectal disease.

Sign In to MPR

SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

Sign in with your MPR account

Keep me signed in Forgot your password?

Don't have one of these accounts?

Create an account for free »

Register for free with MPR

REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

REGISTER FOR FREE WITH A MPR ACCOUNT

Registration acknowledges the Terms and Conditions and Privacy Policy

Already have an account?

Log in now »

FORGET YOUR PASSWORD?

Enter your MPR registration email address to receive a password reset link.

NEW PASSWORD SENT

Already have an account?

Log in now »

ALMOST DONE

Almost Done

Please confirm the information BELOW before Signing In

By registering you agree with our Terms and Conditions and Privacy Policy.

« CANCEL AND GO BACK

Thank you for registering with MPRxOnline.

Please take a moment to tell us a little more about yourself, so we can bring you specialized clinical content that’s most valuable to you.

NEED HELP? Contact Customer Service »